Regulatory

Change in Ascelia Pharma’s management team

2019-10-25
Download

Ascelia Pharma AB (publ) today announced that Ascelia Pharma and the company’s Chief Operation Officer (COO) Dorthe da Graça Thrige have reached an agreement that she will be leaving the company. Her duties will be divided between other senior employees in Ascelia Pharma.

Dorthe da Graça Thrige, who has been with Ascelia Pharma since 2012, will leave the company in December this year. Thereafter, the responsibilities of the COO position will be divided between other senior employees in Ascelia Pharma.

Magnus Corfitzen, CEO, comments:

“Ascelia Pharma has made great progress in the last few years during which the organization has grown, and we expect it to continue to grow in order to meet our strategic goals. I want to thank Dorthe for her dedicated work and contributions to help bring Ascelia Pharma to where we are today. I – and the whole Ascelia team – have enjoyed working with Dorthe and wish her the best of luck in her future endeavours.”

 

For more information, please contact:
Magnus Corfitzen, CEO
Email: moc@ascelia.com
Tel. 46 735 179 110

Mikael Widell, IR & Communications Manager
Email: mw@ascelia.com
Tel: +46 703 11 99 60

 

About Ascelia Pharma
Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral® and Oncoral – currently under development.

Mangoral is a novel contrast agent for MR-scans and is ready for Phase III clinical studies. Mangoral is developed to improve the visualization of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.

2020-03-05

Analysguiden/Carlsquare updates its view on Ascelia Pharma and raises target share price

Today Analysguiden/Carlsquare published an updated equity research report on Ascelia Pharma.  As part of their updated view, they raise their target share price to 41.90 kr from 34.80 kr.
2020-03-02

Issue and repurchase of series C shares for share saving program

Pursuant to the authorization granted by the annual general meeting on 14 November 2019, the board of directors of Ascelia Pharma AB (”Ascelia”) has resolved to issue and immediately thereafter repurchase  510,545 series C shares. The shares are issued and repurchased in accordance with the share saving program LTI 2019, which was adopted by the annual general meeting on 14 November 2019.
2020-02-20

Vator Securities: Ascelia Pharma: A rocket roll out is the key to success

February 20, 2020